Quick Answer
Vistagen Therapeutics, Inc. reported Total Revenue of $1.09 million for fiscal year 2021.
Vistagen Therapeutics, Inc. Total Revenue — Annual History
| Fiscal Year | Total Revenue | YoY Change |
|---|---|---|
| 2021 | $1.09M | — |
| 2020 | $0.00 | — |
| 2018 | $0.00 | -100.0% |
| 2017 | $1.25M | — |
| 2016 | $0.00 | -100.0% |
| 2013 | $200.4K | -85.1% |
| 2012 | $1.34M | -35.2% |
| 2011 | $2.07M | — |
Quarterly Total Revenue
| Quarter Ending | Total Revenue | YoY | QoQ |
|---|---|---|---|
| June 30, 2021 | $354.1K | — | +12.9% |
| December 31, 2020 | $313.6K | — | -6.1% |
| September 30, 2020 | $334.0K | — | — |
| June 30, 2020 | $0.00 | — | — |
| December 31, 2019 | $0.00 | — | — |
| September 30, 2019 | $0.00 | — | — |
| December 31, 2017 | $0.00 | -100.0% | -100.0% |
| December 31, 2016 | $1.25M | — | — |
- Over the 2011–2021 period, Vistagen Therapeutics, Inc.’s total revenue has declined by 47.4% (from $2.07 million to $1.09 million).
- The most recent figure is from Vistagen Therapeutics, Inc.’s fiscal year 2020 report (Form 10-K), filed with the SEC on June 29, 2021.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: